Literature DB >> 16181002

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.

Dieter Hochrainer1, Hubert Hölz, Christoph Kreher, Luigi Scaffidi, Michael Spallek, Herbert Wachtel.   

Abstract

Apart from particle size distribution, spray velocity is one of the most important aerosol characteristics that influence lung deposition of inhaled drugs. The time period over which the aerosol is released (spray duration) is also important for coordination of inhalation. Respimat Soft Mist Inhaler (SMI) is a new generation, propellant-free inhaler that delivers drug to the lung much more efficiently than pressurised metered dose inhalers (pMDIs). The objective of this study was to compare the velocity and spray duration of aerosol clouds produced by Respimat SMI with those from a variety of chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) pMDIs. All inhalers contained solutions or suspensions of bronchodilators. A videorecording method was used to determine the aerosol velocity. For spray duration, the time for generation of the Soft Mist by Respimat SMI was initially determined using three different methods (videorecording [techniques A and B], laser light diffraction and rotating disc). Videorecording was then used to compare the spray duration of Respimat SMI with those from the other inhalers. The Soft Mist produced by Respimat SMI moved much more slowly and had a more prolonged duration than aerosol clouds from pMDIs (mean velocity at a 10-cm distance from the nozzle: Respimat SMI, 0.8 m/sec; pMDIs, 2.0-8.4 m/sec; mean duration: Respimat SMI, 1.5 sec; pMDIs, 0.15-0.36 sec). These characteristics should result in improved lung and reduced oropharyngeal deposition, and are likely to simplify coordination of inhaler actuation and inhalation compared with pMDIs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181002     DOI: 10.1089/jam.2005.18.273

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  40 in total

1.  Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.

Authors:  P Worth Longest; Geng Tian; Ross L Walenga; Michael Hindle
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

Review 2.  A path to successful patient outcomes through aerosol drug delivery to children: a narrative review.

Authors:  Arzu Ari
Journal:  Ann Transl Med       Date:  2021-04

3.  Precision Ocular Drug Delivery Via Aerosol Ring Vortices.

Authors:  Matthew J Herpin; Hugh D C Smyth
Journal:  Pharm Res       Date:  2017-08-07       Impact factor: 4.200

4.  Production and characterization of drug-loaded toroidal vortices from a novel ocular drug delivery device.

Authors:  Matthew J Herpin; Dominik Ebi; Noel T Clemens; Hugh D C Smyth
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

5.  Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

Authors:  Geng Tian; P Worth Longest; Xiang Li; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-01-03       Impact factor: 2.849

6.  Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies.

Authors:  Eric Bateman; Dave Singh; David Smith; Bernd Disse; Lesley Towse; Dan Massey; Jon Blatchford; Demetri Pavia; Rick Hodder
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

Review 7.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Authors:  Donald P Tashkin; Leonardo M Fabbri
Journal:  Respir Res       Date:  2010-10-29

8.  Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.

Authors:  Rick Hodder; Pat Ray Reese; Terra Slaton
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-06-11

Review 9.  Use of Respimat Soft Mist inhaler in COPD patients.

Authors:  Paula Anderson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.

Authors:  Richard Hodder; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.